Alemtuzumab
Showing 51 - 75 of 419
Idiopathic Pulmonary Fibrosis, Emphysema or COPD Trial in Pittsburgh (CD3/CD19 negative hematopoietic stem cells, Rituximab,
Recruiting
- Idiopathic Pulmonary Fibrosis
- Emphysema or COPD
- CD3/CD19 negative hematopoietic stem cells
- +6 more
-
Pittsburgh, Pennsylvania
- +1 more
Feb 9, 2022
Novel Peri Infusion Regimen on Infusion Associated Reactions
Active, not recruiting
- Frequency of Infusion Reactions in Novel Versus Standard Protocol in Multiple Sclerosis
- Alemtuzumab Injection
-
Halifax, Nova Scotia, CanadaMaritime Neurology
Nov 11, 2020
Long-term Immune Regulation Following Treatment With Lemtrada®.
Terminated
- Multiple Sclerosis
- Assessment of leukocyte function.
-
Los Angeles, CaliforniaUniversity of Southern California, Department of Neurology
Dec 15, 2020
Crohn's Disease Trial in Pittsburgh (autologous CD34-selected peripheral blood stem cells transplant, Alemtuzumab, ATG)
Recruiting
- Crohn's Disease
- autologous CD34-selected peripheral blood stem cells transplant
- +8 more
-
Pittsburgh, Pennsylvania
- +1 more
Feb 9, 2022
Aplastic Anemia Trial run by the NHLBI (Campath-1H, r-ATG, CsA)
Completed
- Aplastic Anemia
- Campath-1H
- +2 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center, 9000 Rockville Pi
Jul 2, 2021
Systemic Sclerosis, Diffuse Sclerosis Systemic, Interstitial Lung Disease Trial in Pittsburgh (Cyclophosphamide, Mesna,
Recruiting
- Systemic Sclerosis
- +3 more
- Cyclophosphamide
- +8 more
-
Pittsburgh, Pennsylvania
- +2 more
Dec 17, 2021
Leukemia, Erythroblastic, Acute, MDS Trial in New York (5-Azacytidine, Fludarabine, Melphalan)
Completed
- Leukemia, Erythroblastic, Acute
- Myelodysplastic Syndromes
- 5-Azacytidine
- +4 more
-
New York, New YorkWeill Cornell Medical College
Aug 25, 2021
Multiple Sclerosis Trial in Worldwide (Alemtuzumab (GZ402673))
Terminated
- Multiple Sclerosis
- Alemtuzumab (GZ402673)
-
New York, New York
- +12 more
Apr 21, 2022
Sickle Cell Disease, Beta Thalassemia-Major Trial in New Hyde Park (alemtuzumab (Campath IH), Fludarabine, Melphalan)
Completed
- Sickle Cell Disease
- Beta Thalassemia-Major
- alemtuzumab (Campath IH)
- +6 more
-
New Hyde Park, New YorkCohen Children's Medical Center of New York
Jul 30, 2021
Acute Lymphoblastic Leukemia Trial in La Jolla, San Diego (Alemtuzumab, Clofarabine)
Terminated
- Acute Lymphoblastic Leukemia
- Alemtuzumab
- Clofarabine
-
La Jolla, California
- +2 more
Jul 29, 2020
Sickle Cell Disease, Stem Cell Transplant Complications, Red Blood Cell Disorder Trial in Calgary (Alemtuzumab, Total Body
Recruiting
- Sickle Cell Disease
- +3 more
- Alemtuzumab
- +2 more
-
Calgary, Alberta, CanadaAlberta Children's Hospital
May 25, 2021
Severe Aplastic Anemia, Refractory, Severe Aplastic Anemia, Relapse Trial run by the NHLBI (Alemtuzumab (Campath ),
Completed
- Severe Aplastic Anemia, Refractory
- Severe Aplastic Anemia, Relapse
- Alemtuzumab (Campath )
- Cyclosporine
-
Bethesda, MarylandNational Institutes of Health Clinical Center, 9000 Rockville Pi
Jun 29, 2020
B-cell Acute Lymphoblastic Leukemia Trial in France, United States (UCART22)
Recruiting
- B-cell Acute Lymphoblastic Leukemia
- UCART22
- CLLS52
-
Los Angeles, California
- +10 more
Sep 23, 2022
Sickle Cell Disease, GVHD Trial in United States (Diphenhydramine, Acetaminophen, Methylprednisolone)
Active, not recruiting
- Sickle Cell Disease
- Graft Versus Host Disease
- Diphenhydramine
- +15 more
-
Washington, District of Columbia
- +6 more
Aug 4, 2021
Inherited Immune Deficiencies Trial run by the NIAID (Campath 1H, Busulfan, Horse Anti-human Thymocyte Globulin (h-ATG))
Completed
- Inherited Immune Deficiencies
- Campath 1H
- +4 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center, 9000 Rockville Pi
Apr 20, 2021
B-cell Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia, Stage 0 Chronic Lymphocytic Leukemia Trial in
Completed
- B-cell Chronic Lymphocytic Leukemia
- +4 more
- alemtuzumab
- +9 more
-
Rochester, MinnesotaMayo Clinic
Jun 11, 2020
Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma Trial in New York (Bendamustine, Carmustine, Etoposide)
Completed
- Hodgkin's Lymphoma
- Non-Hodgkin's Lymphoma
- Bendamustine
- +8 more
-
New York, New YorkWeill Cornell Medical College
Feb 1, 2021
Disorder Related to Renal Transplantation Trial in Madison (Campath-1H)
Terminated
- Disorder Related to Renal Transplantation
-
Madison, WisconsinUniversity of Wisconsin Hospital and Clinics
Aug 31, 2020
Relapsing Remitting Multiple Sclerosis Trial in Worldwide (alemtuzumab GZ402673)
Completed
- Relapsing Remitting Multiple Sclerosis
- alemtuzumab GZ402673
-
Cullman, Alabama
- +130 more
Mar 21, 2022
Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis Trial in United
Recruiting
- Relapsing Multiple Sclerosis
- +2 more
- Autologous Hematopoietic Stem Cell Transplantation
- Best Available Therapy (BAT)
-
Palo Alto, California
- +20 more
Jan 25, 2023
Sickle Cell Disease Trial run by the National Heart, Lung, and Blood Institute (NHLBI) (Non-myeloablative haploidentical
Not yet recruiting
- Sickle Cell Disease
- Non-myeloablative haploidentical peripheral blood stem celltransplantation with briquilimab and abatacept
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Dec 4, 2023
Allogeneic Hematopoietic Cell Transplantation Trial in Cincinnati (Alemtuzumab)
Completed
- Allogeneic Hematopoietic Cell Transplantation
- Alemtuzumab
-
Cincinnati, OhioCincinnati Children's Hospital Medical Center
Oct 3, 2019
Severe Aplastic Anemia Who Relapsed After Immunosuppressive
Active, not recruiting
- Severe Aplastic Anemia
-
Bethesda, MarylandNational Heart, Lung and Blood Institute (NHLBI)
Apr 7, 2022